Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 752-754

  Yahata, Tetsuro ^a   Nishikawa, Nobumichi ^a   Aoki, Yoichi ^a   Tanaka, Kenichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Ovarian cancer; Taxol; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; BICARBONATE; CARBOPLATIN; DOCETAXEL; FUROSEMIDE; IRINOTECAN; MITOMYCIN; PACLITAXEL;

ADULT; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CASE REPORT; DISEASE ASSOCIATION; FATIGUE; FEMALE; HUMAN; OLIGURIA; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

ADENOCARCINOMA, CLEAR CELL; ADULT; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR LYSIS SYNDROME;

EID: 33750154440     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.003     Document Type: Article

References (10)

1. Baeksgaard L., and Sorensen J.B. Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol 51 (2003) 187-192
2. Drakos P., Bar-Ziv J., and Catane R. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 17 (1994) 502-505
3. Oztop I., Demirkan B., Yaren A., Tarhan O., Sengul B., Ulukus C., et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori 90 (2004) 514-516
4. Kurt M., Eren O.O., Engin H., and Guler N. Tumor lysis syndrome following a single dose of capecitabine. Ann Pharmacother 38 (2004) 902
5. Chan J.K., Lin S.S., McMeekin D.S., and Berman M.L. Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer. J Clin Oncol 23 (2005) 6794-6795
6. Bilgrami S.F., and Fallon B.G. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 21 (1993) 521-524
7. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., and Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1748-1753
8. McGuire III W.P. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 21 (2003) 133-135
9. Markman M., Blessing J., Rubin S.C., Connor J., Hanjani P., and Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m(2)) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 436-440
10. Ustundag Y., Boyacioglu S., Haznedaroglu I.C., and Baltali E. Acute tumor lysis syndrome associated with paclitaxel. Ann Pharmacother 31 (1997) 1548-1549